Recent Updates
Recently added Catalysts
SKYE Negative Sentiment

SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Key Takeaway: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Skye Bioscience, Inc. for alleged violations of federal securities laws. The lawsuit seeks damages for investors who acquired Skye securities during a specified Class Period. Accusations include misleading statements regarding the effectiveness of nimacimab and its prospects. Affected investors have until January 16, 2026, to request to be appointed as lead plaintiffs in the case.
Price reaction · baseline $0.93 (2025-12-19 close) · 3 other SKYE headline(s) in the window, move may be shared
day 0 close
-1.1%

Market Sentiment Analysis

CONCERNS & RISKS

  • The class action lawsuit alleges that Skye made materially false and misleading statements.
  • Nimacimab's effectiveness was reportedly overstated, impacting investor trust.
  • The lawsuit highlights significant claims of federal securities law violations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity

Full Press Release Details

NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Skye securities between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/SKYE.
The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Skye’s business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/SKYE. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Skye you have until January 16, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller

Frequently Asked Questions

What is the class action lawsuit against Skye Bioscience?

The lawsuit seeks damages for alleged federal securities law violations by Skye and its officers, concerning investor purchases from November 4, 2024, to October 3, 2025.

What false statements are alleged in the lawsuit?

The lawsuit claims that Defendants misrepresented nimacimab's effectiveness and overstated its prospects, leading to materially misleading public statements.

How can I join the class action lawsuit?

Investors can join by visiting bgandg.com/SKYE and contacting Bronstein, Gewirtz & Grossman, LLC for details.

What is the deadline to request lead plaintiff status?

The deadline to request lead plaintiff status is January 16, 2026.

Is there a cost for joining the lawsuit?

There is no cost to join; the firm operates on a contingency fee basis, only charging if successful.

Last updated: Dec 22, 2025